View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Primeenergy Resources Corp: 1 director

A director at Primeenergy Resources Corp sold 4,568 shares at 100.091USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

 PRESS RELEASE

Earth Day 2024: Coherent Corp. Announces Milestones in its Sustainabil...

Earth Day 2024: Coherent Corp. Announces Milestones in its Sustainability Journey Company Sets a 2040 Net-Zero Goal, Increases Its Renewable Electricity Use to 70%, and Joins the Responsible Business Alliance PITTSBURGH, April 23, 2024 (GLOBE NEWSWIRE) -- In support of Earth Day 2024, Coherent Corp. (NYSE: COHR), a global leader in materials, networking, and lasers, announced today that the company is now obtaining approximately 70% of its global electricity needs from renewable energy sources. In total, this represents over 500 million kWh of renewable electricity per year, thereby avo...

 PRESS RELEASE

EQS-News: Quartalsmitteilung für das erste Quartal 2024

EQS-News: AMADEUS FIRE AG / Schlagwort(e): Quartals-/Zwischenmitteilung Quartalsmitteilung für das erste Quartal 2024 23.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Quartalsmitteilung erstes Quartal 2024 Die Amadeus Fire Group konnte in den ersten drei Monaten des Jahres 2024 den Umsatz um 3,4 Prozent steigern. Die Weiterbildungsumsätze haben sich, wie auch im Jahresverlauf 2023, weiterhin deutlich positiv entwickelt, während die Personaldienstleistungsumsätze zum Jahresstart leicht unterhalb des Vorjahres lagen....

 PRESS RELEASE

EQS-News: HAMBORNER REIT AG starts 2024 with further growth in revenue...

EQS-News: HAMBORNER REIT AG / Key word(s): Quarterly / Interim Statement/Quarter Results HAMBORNER REIT AG starts 2024 with further growth in revenue and earnings 23.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE HAMBORNER REIT AG starts 2024 with further growth in revenue and earnings Solid operating performance Income from rents and leases up 3.1% to €23.4 million FFO rises by 2.6% to €14.0 million Net asset value (NAV) per share of €10.19 (up +1.7% YTD) Confirmation of forecast for full-year 2024 ...

 PRESS RELEASE

EQS-News: Quarterly statement three months 2024

EQS-News: AMADEUS FIRE AG / Key word(s): Quarterly / Interim Statement Quarterly statement three months 2024 23.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Quarterly statement three months 2024 The Amadeus Fire Group increased its revenue by 3.4 percent in the first three months of 2024. As in the course of 2023, revenue for training continued to develop positively, while revenue for personnel services was down slightly year-on-year at the start of the year. At the end of the first quarter, the Group's operating EBITA...

 PRESS RELEASE

EQS-News: HAMBORNER REIT AG startet mit erneutem Umsatz- und Ergebnisz...

EQS-News: HAMBORNER REIT AG / Schlagwort(e): Quartals-/Zwischenmitteilung/Quartalsergebnis HAMBORNER REIT AG startet mit erneutem Umsatz- und Ergebniszuwachs ins Jahr 2024 23.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG HAMBORNER REIT AG startet mit erneutem Umsatz- und Ergebniszuwachs ins Jahr 2024 Solide operative Geschäftsentwicklung Erhöhung der Miet- und Pachterlöse um 3,1 % auf 23,4 Mio. Euro Anstieg des FFO um 2,6 % auf 14,0 Mio. Euro Nettovermögenswert (NAV) je Aktie bei 10,19 Euro (...

ABGSC Strategy Research ... (+3)
  • ABGSC Strategy Research
  • Amanda Alla
  • Christer Linde

SE positioning as of end of March 2024 & trading ideas

SE positioning update as of end of March 2024.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen

Decent sales and improving margin

ABGSCe revenue slightly ahead of cons. into Q1. Beyfortus and efan alfa royalty income to boost adj. EBITA margins. Attractive growth valuation, key value inflection points coming - BUY.

 PRESS RELEASE

BenevolentAI Provides an Update on Its Business Priorities

LONDON--(BUSINESS WIRE)-- Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities. Going forward the Company will focus on its AI-driven drug discovery collaboration and proprietary pipeline revenue generating pillars, following recent successes in these areas. The Board believes this focus will likely bring the greatest potential return for shareholders. Following completion of the market assessment of its Knowledge Exploratio...

 PRESS RELEASE

LHV Group unaudited financial results for Q1 2024

LHV Group unaudited financial results for Q1 2024 For LHV, the first quarter of the year demonstrated strong results, affected by the higher-than-planned increase in business volumes and the interest environment remaining at the same level. In Q1 of 2024, AS LHV Group generated EUR 40.7 million in net profit. AS LHV Pank earned EUR 36.8 million and LHV Bank Limited EUR 4.9 million in net profit. AS LHV Varahaldus generated a net loss of EUR 220 thousand in Q1, and AS LHV Kindlustus generated a net profit of EUR 256 thousand. The return on equity attributable to the shareholders of t...

 PRESS RELEASE

Renault Group: 2024 Q1 Group revenue at €11.7 billion, +5.9% at consta...

Renault Group: 2024 Q1 Group revenue at €11.7 billion, +5.9% at constant exchange rate; in the starting-blocks for the upcoming product offensive Press ReleaseApril 23, 2024       2024 Q1: Group revenue at €11.7 billion, +5.9% at constant exchange rate1;in the starting-blocks for the upcoming product offensive Renault Group worldwide sales amounted to 549,099 vehicles in the first quarter, up 2.6% versus 2023 Q1. In Europe2, Group sales were up 4.3%. Group revenue at €11,707 million, +1.8% and +5.9% at constant exchange rate1 versus 2023 Q1. Automotive revenue at €10,446 mi...

 PRESS RELEASE

Renault Group : Chiffre d’affaires Groupe du 1er trimestre 2024 à 11,7...

Renault Group : Chiffre d’affaires Groupe du 1er trimestre 2024 à 11,7 milliards d’euros, +5,9 % à taux de change constants ; dans les starting-blocks pour l'offensive produits à venir Communiqué de presse 23 avril 2024          1er trimestre 2024 : Chiffre d’affaires Groupe à 11,7 milliards d’euros, +5,9 % à taux de change constants1 ; dans les starting-blocks pour l'offensive produits à venir Les ventes mondiales du Groupe s’élèvent à 549 099 véhicules au 1er trimestre, en hausse de 2,6 % par rapport au 1er trimestre 2023. En Europe2, les ventes du Groupe augmentent de 4,...

 PRESS RELEASE

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint...

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfull...

 PRESS RELEASE

Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib po...

Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire   L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire Des données pivots de la première étude de phase III d’un BTKi dans la thrombocytopénie immune (TPI) montrent que le rilzabrutinib a le potentiel d’apporter un bénéfice clinique important aux patients atteints d’une TPI. Soumissions réglementaires prévues aux États-Unis et dans l’Union euro...

 PRESS RELEASE

KKR and Impilo Announce Strategic Partnership Together With Management...

STOCKHOLM & LONDON--(BUSINESS WIRE)-- Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions. KKR and Impilo will work together with Immedica’s management team to support Immedica’s continued growth, includ...

 PRESS RELEASE

eQ Plc’s interim report Q1 2024 – eQ’s profit fell

eQ Plc’s interim report Q1 2024 – eQ’s profit fell eQ Plc interim report23 April 2024 at 8:00 AM January to March 2024 in brief During the financial period, the Group's net revenue totalled EUR 16.5 million (EUR 17.7 million from 1 Jan. to 31 Mar. 2023). The Group’s net fee and commission income was EUR 16.0 million (EUR 17.5 million). The Group’s operating profit fell by 12% to EUR 8.8 million (EUR 10.0 million).The Group’s profit was EUR 7.0 million (EUR 7.9 million). The consolidated earnings per share were EUR 0.17 (EUR 0.20).The net revenue of the Asset Management ...

 PRESS RELEASE

eQ Oyj:n osavuosikatsaus Q1 2024 – eQ:n tulos laski

eQ Oyj:n osavuosikatsaus Q1 2024 – eQ:n tulos laski eQ Oyj osavuosikatsaus23.4.2024, klo 8:00 Tammi-maaliskuu 2024 lyhyesti Konsernin nettoliikevaihto oli katsauskaudella 16,5 miljoonaa euroa (17,7 MEUR 1.1.-31.3.2023). Konsernin nettopalkkiotuotot olivat 16,0 miljoonaa euroa (17,5 MEUR). Konsernin liikevoitto laski 12 prosenttia ja oli 8,8 miljoonaa euroa (10,0 MEUR).Konsernin tulos oli 7,0 miljoonaa euroa (7,9 MEUR). Konsernin osakekohtainen tulos oli 0,17 euroa (0,20 euroa).Varainhoito-segmentin nettoliikevaihto laski 11 prosenttia 15,1 miljoonaan euroon ...

 PRESS RELEASE

LHV Groupi 2024. aasta I kvartali auditeerimata majandustulemused

LHV Groupi 2024. aasta I kvartali auditeerimata majandustulemused LHV jaoks oli aasta esimene kvartal tugevate tulemustega, mida mõjutasid ärimahtude plaanitust suurem kasv ja intressikeskkonna samal tasemel püsimine. AS LHV Group teenis 2024. aasta I kvartalis 40,7 miljonit eurot puhaskasumit. AS LHV Pank teenis puhaskasumit 36,8 miljonit eurot ja LHV Bank Limited 4,9 miljonit eurot. AS-i LHV Varahaldus I kvartali puhaskahjumiks jäi 220 tuhat eurot ja AS-i LHV Kindlustus puhaskasumiks kogunes 256 tuhat eurot. Grupi aktsionäridele kuuluva omakapitali tootlus oli I kvartalis 28,5%. ...

Unit4 Group Holding B.V.: Proposed €175 million add-on is credit negat...

The transaction will increase leverage and reduce free cash flow generation at the restricted group.

Benefit Street Partners CLO XXXIV, Ltd.: Pre-Sale Report

This pre-sale report provides a detailed rating rationale for the transaction.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch